Managing Symptoms over Time



The importance of quality of life (QOL) among cancer survivors is second only to survival [1]. A cancer survivor’s general well-being significantly impacts his or her ability to successfully engage in everyday activities and to adapt to living with cancer [2], and it has been shown to be a powerful predictor of survival and treatment-related toxicity among cancer survivors [3–7]. How well a cancer survivor copes with the changes resulting from the cancer and its treatment depends on a variety of physical and psychosocial factors that determine the cancer survivor’s overall QOL.


Cancer Survivor Breast Cancer Survivor Comorbid Illness Survivorship Care Plan Cardiovascular Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Oncology, ASoC. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671–9.Google Scholar
  2. 2.
    Loescher LJ, Clark L, Atwood JR, Leigh S, Lamb G. The impact of the cancer experience on long-term survivors. Oncol Nurs Forum. 1990;17(2):223–9.PubMedGoogle Scholar
  3. 3.
    Herndon 2nd JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999;85(2):333–40.PubMedGoogle Scholar
  4. 4.
    Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26(8):1355–63.PubMedGoogle Scholar
  5. 5.
    Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, et al. Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17(11):1698–704.PubMedGoogle Scholar
  6. 6.
    Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, et al. Validation of patient’s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2008;26(12):2020–6.PubMedGoogle Scholar
  7. 7.
    Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001;31(2–3):233–40.PubMedGoogle Scholar
  8. 8.
    Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003;58(1):82–91.PubMedGoogle Scholar
  9. 9.
    Hoffman KE, McCarthy EP, Recklitis CJ, Ng AK. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med. 2009;169(14):1274–81.PubMedGoogle Scholar
  10. 10.
    Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96(17):1322–30.PubMedGoogle Scholar
  11. 11.
    Richardson LC, Wingo PA, Zack MM, Zahran HS, King JB. Health-related quality of life in cancer survivors between ages 20 and 64 years: population-based estimates from the Behavioral Risk Factor Surveillance System. Cancer. 2008;112(6):1380–9.PubMedGoogle Scholar
  12. 12.
    Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106(4):751–8.PubMedGoogle Scholar
  13. 13.
    Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104(11 Suppl):2565–76.PubMedGoogle Scholar
  14. 14.
    Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–91.PubMedGoogle Scholar
  15. 15.
    Mols F, van de Poll-Franse LV, Vingerhoets AJ, Hendrikx A, Aaronson NK, Houterman S, et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer. 2006;107(9):2186–96.PubMedGoogle Scholar
  16. 16.
    Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. J Natl Compr Cancer Netw. 2009;7(8):883–93.Google Scholar
  17. 17.
    Ganz PA. Psychological and social aspects of breast cancer. Oncology (Williston Park). 2008;22(6):642–46.Google Scholar
  18. 18.
    Ferrans CE. Development of a quality of life index for patients with cancer. Oncol Nurs Forum. 1990;17(3 Suppl):15–19.PubMedGoogle Scholar
  19. 19.
    Padilla GV, Ferrell B, Grant MM, Rhiner M. Defining the content domain of quality of life for cancer patients with pain. Cancer Nurs. 1990;13(2):108–15.PubMedGoogle Scholar
  20. 20.
    Spiker B. Quality of life assessments in clinical trials. New York: Raven; 1990.Google Scholar
  21. 21.
    Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–31.PubMedGoogle Scholar
  22. 22.
    Armstrong TS. Symptoms experience: a concept analysis. Oncol Nurs Forum. 2003;30(4):601–6.PubMedGoogle Scholar
  23. 23.
    Barsevick AM. The concept of symptom cluster. Semin Oncol Nurs. 2007;23(2):89–98.PubMedGoogle Scholar
  24. 24.
    Barsevick AM. The elusive concept of the symptom cluster. Oncol Nurs Forum. 2007;34(5):971–80.PubMedGoogle Scholar
  25. 25.
    Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001;28(3):465–70.PubMedGoogle Scholar
  26. 26.
    Cleeland CS, Reyes-Gibby CC. When is it justified to treat symptoms? Measuring symptom burden. Oncology (Williston Park). 2002;16(9 Suppl 10):64–70.Google Scholar
  27. 27.
    Kuhnt S, Ernst J, Singer S, Ruffer JU, Kortmann RD, Stolzenburg JU, et al. Fatigue in cancer survivors – prevalence and correlates. Onkologie. 2009;32(6):312–7.PubMedGoogle Scholar
  28. 28.
    Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer. 2006;42(3):327–33.PubMedGoogle Scholar
  29. 29.
    Hjermstad MJ, Fossa SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH. Fatigue in long-term Hodgkin’s Disease survivors: a follow-up study. J Clin Oncol. 2005;23(27):6587–95.PubMedGoogle Scholar
  30. 30.
    Orre IJ, Fossa SD, Bremnes R, Dahl O, Klepp O, et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res. 2008;64(4):363–71.PubMedGoogle Scholar
  31. 31.
    Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–53.PubMedGoogle Scholar
  32. 32.
    Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, et al. Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol. 2003;21(18):3512–9.PubMedGoogle Scholar
  33. 33.
    Servaes P, van der Werf S, Prins J, Verhagen S, Bleijenberg G. Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer. 2001;9(1):11–7.PubMedGoogle Scholar
  34. 34.
    Ruffer JU, Flechtner H, Tralls P, Josting A, Sieber M, Lathan B, et al. Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer. 2003;39(15):2179–86.PubMedGoogle Scholar
  35. 35.
    Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353–60.PubMedGoogle Scholar
  36. 36.
    Schwartz AL. Fatigue in long-term cancer survivors. Oncology (Williston Park). 2009;23(8 Suppl):27. 33–4.Google Scholar
  37. 37.
    Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009;24 Suppl 2:S389–94.PubMedGoogle Scholar
  38. 38.
    Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med. 1998;21(1):1–18.PubMedGoogle Scholar
  39. 39.
    Richardson A. Fatigue in cancer patients: a review of the literature. Eur J Cancer Care (Engl). 1995;4(1):20–32.Google Scholar
  40. 40.
    Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998;7(4):301–10.PubMedGoogle Scholar
  41. 41.
    Verbeek J, Spelten E, Kammeijer M, Sprangers M. Return to work of cancer survivors: a prospective cohort study into the quality of rehabilitation by occupational physicians. Occup Environ Med. 2003;60(5):352–7.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Spelten ER, Verbeek JH, Uitterhoeve AL, Ansink AC AC, Van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer. 2003;39(11):1562–7.PubMedGoogle Scholar
  43. 43.
    Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994;28(4):847–56.PubMedGoogle Scholar
  44. 44.
    Norum J, Wist EA. Quality of life in survivors of Hodgkin’s disease. Qual Life Res. 1996;5(3):367–74.PubMedGoogle Scholar
  45. 45.
    Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM, Fields KK. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer. 1997;5(1):44–52.PubMedGoogle Scholar
  46. 46.
    Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16(5):1689–96.PubMedGoogle Scholar
  47. 47.
    Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum. 1998;25(4):677–84.PubMedGoogle Scholar
  48. 48.
    Piper BF, Lindsey AM, Dodd MJ. Fatigue mechanisms in cancer patients: developing nursing theory. Oncol Nurs Forum. 1987;14(6):17–23.PubMedGoogle Scholar
  49. 49.
    Aistars J. Fatigue in the cancer patient: a conceptual approach to a clinical problem. Oncol Nurs Forum. 1987;14(6):25–30.PubMedGoogle Scholar
  50. 50.
    Winningham ML, Nail LM, Burke MB, Brophy L, Cimprich B, Jones LS, et al. Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum. 1994;21(1):23–36.PubMedGoogle Scholar
  51. 51.
    Karabulu N, Erci B, Ozer N, Ozdemir S. Symptom clusters and experiences of patients with cancer. J Adv Nurs. 2010;66(5):1011–21.PubMedGoogle Scholar
  52. 52.
    Evensen JF, Bjordal K, Knutsen BH, Olsen DR, Store G, Tausjo JE. Side effects and quality of life after inadvertent radiation overdosage in brachytherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52(4):944–52.PubMedGoogle Scholar
  53. 53.
    Small Jr W, Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research? JAMA. 2005;294(20):2635–7.PubMedGoogle Scholar
  54. 54.
    Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003;104(1–2):1–13.PubMedGoogle Scholar
  55. 55.
    Tasmuth T, von Smitten K, Hietanen P, Kataja M, Kalso E. Pain and other symptoms after different treatment modalities of breast cancer. Ann Oncol. 1995;6(5):453–9.PubMedGoogle Scholar
  56. 56.
    Tasmuth T, von Smitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer. 1996;74(12):2024–31.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Peuckmann V, Ekholm O, Rasmussen NK, Groenvold M, Christiansen P, Moller S, et al. Chronic pain and other sequelae in long-term breast cancer survivors: nationwide survey in Denmark. Eur J Pain. 2009;13(5):478–85.PubMedGoogle Scholar
  58. 58.
    Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000;93(4):1123–33.PubMedGoogle Scholar
  59. 59.
    Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18):1985–92.PubMedGoogle Scholar
  60. 60.
    Given CW, Given B, Azzouz F, Kozachik S, Stommel M. Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. J Pain Symptom Manage. 2001;21(6):456–66.PubMedGoogle Scholar
  61. 61.
    Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Investig. 2003;21(3):439–51.Google Scholar
  62. 62.
    Visovsky C, Meyer RR, Roller J, Poppas M. Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs. 2008;12(2):243–7.PubMedGoogle Scholar
  63. 63.
    Visovsky C, Daly BJ. Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. J Am Acad Nurse Pract. 2004;16(8):353–9.PubMedGoogle Scholar
  64. 64.
    Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Institute NC, editor. New malignancies among cancer survivors: SEER Cancer Registries 1973–2000. Bethesda: National Cancer Institute; 2006. p. 181–205.Google Scholar
  65. 65.
    Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.Google Scholar
  66. 66.
    Delwail V, Jais JP, Colonna P, Andrieu JM. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin’s disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002;118(1):189–94.PubMedGoogle Scholar
  67. 67.
    van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, et al. Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12(5):1063–73.PubMedGoogle Scholar
  68. 68.
    Henry-Amar M. Second cancers after treatment of Hodgkin’s disease: experience at the International Database on Hodgkin’s disease (IDHD). Bull Cancer. 1992;79(4):389–91.PubMedGoogle Scholar
  69. 69.
    Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin’s disease. N Engl J Med. 1990;322(1):7–13.PubMedGoogle Scholar
  70. 70.
    Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol. 2003;30(6):740–8.PubMedGoogle Scholar
  71. 71.
    Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343(15):1086–94.PubMedGoogle Scholar
  72. 72.
    Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55(3):231–40.PubMedGoogle Scholar
  73. 73.
    van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005;41(7):1051–7.PubMedGoogle Scholar
  74. 74.
    Vulto AJ, Lemmens VE, Louwman MW, Janssen-Heijnen ML, Poortmans PH, Lybeert ML, et al. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer. 2006;106(12):2734–42.PubMedGoogle Scholar
  75. 75.
    Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen ML. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer. 2006;42(17):3015–21.PubMedGoogle Scholar
  76. 76.
    Le Corroller-Soroano AG, Bouhnik AD, Preau M, Malavolti L, Julian-Reynier C, Auquier P, et al. Does cancer survivors’ health-related quality of life depend on cancer type? Findings from a large French national sample 2 years after cancer diagnosis. Eur J Cancer Care (Engl). 2011;20(1):132–40.Google Scholar
  77. 77.
    Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.PubMedGoogle Scholar
  78. 78.
    Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 2001;10(2):156–65.PubMedGoogle Scholar
  79. 79.
    Deimling GT, Kahana B, Bowman KF, Schaefer ML. Cancer survivorship and psychological distress in later life. Psychooncology. 2002;11(6):479–94.PubMedGoogle Scholar
  80. 80.
    Komaki R, Meyers CA, Shin DM, Garden AS, Byrne K, Nickens JA, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33(1):179–82.PubMedGoogle Scholar
  81. 81.
    Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93.PubMedGoogle Scholar
  82. 82.
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–6.Google Scholar
  83. 83.
    van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210–8.PubMedGoogle Scholar
  84. 84.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18(14):2695–701.PubMedGoogle Scholar
  85. 85.
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85(3):640–50.PubMedGoogle Scholar
  86. 86.
    Ferrell BR, Grant MM, Funk B, Otis-Green S, Garcia N. Quality of life in breast cancer survivors as identified by focus groups. Psychooncology. 1997;6(1):13–23.PubMedGoogle Scholar
  87. 87.
    Ferrell BR, Hassey Dow K. Quality of life among long-term cancer survivors. Oncology (Williston Park). 1997;11(4):565–8, 571.Google Scholar
  88. 88.
    Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). 2000;14(1):75–9.Google Scholar
  89. 89.
    Kvale EA, Clay OJ, Ross-Meadows LA, McGee JS, Edwards JD, Unverzagt FW, et al. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial. Eur J Cancer Care (Engl). 2010;19(1):110–7.Google Scholar
  90. 90.
    van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology. 2008;17(11):1137–45.PubMedGoogle Scholar
  91. 91.
    Johnson Vickberg SM. Fears about breast cancer recurrence. Cancer Pract. 2001;9(5):237–43.PubMedGoogle Scholar
  92. 92.
    Lee-Jones C, Humphris G, Dixon R, Hatcher MB. Fear of cancer recurrence – a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology. 1997;6(2):95–105.PubMedGoogle Scholar
  93. 93.
    Clough-Gorr KM, Ganz PA, Silliman RA. Older breast cancer survivors: factors associated with change in emotional well-being. J Clin Oncol. 2007;25(11):1334–40.PubMedGoogle Scholar
  94. 94.
    Baider L, Andritsch E, Uziely B, Goldzweig G, Ever-Hadani P, Hofman G, et al. Effects of age on coping and psychological distress in women diagnosed with breast cancer: review of literature and analysis of two different geographical settings. Crit Rev Oncol Hematol. 2003;46(1):5–16.PubMedGoogle Scholar
  95. 95.
    Knobf MT. Psychosocial responses in breast cancer survivors. Semin Oncol Nurs. 2007;23(1):71–83.PubMedGoogle Scholar
  96. 96.
    Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs. 2001;17(4):241–8.PubMedGoogle Scholar
  97. 97.
    Ferrell BR, Dow KH, Leigh S, Ly J, Gulasekaram P. Quality of life in long-term cancer survivors. Oncol Nurs Forum. 1995;22(6):915–22.PubMedGoogle Scholar
  98. 98.
    McEvoy MD, McCorkle R. Quality of life issues in patients with disseminated breast cancer. Cancer. 1990;66(6 Suppl):1416–21.PubMedGoogle Scholar
  99. 99.
    Kornblith AB. Psychosocial adaptation of cancer survivors. New York: Oxford University Press; 1998.Google Scholar
  100. 100.
    Hoffman B. Cancer survivors at work: job problems and illegal discrimination. Oncol Nurs Forum. 1989;16(1):39–43.PubMedGoogle Scholar
  101. 101.
    Taylor SE. Adjustment to threatening events: a theory of cognitive adaptation. Am Psychol. 1983;38:1161–73.Google Scholar
  102. 102.
    Pinquart M, Frohlich C. Psychosocial resources and subjective well-being of cancer patients. Psychol Health. 2009;24(4):407–21.PubMedGoogle Scholar
  103. 103.
    Carver CS, Smith RG, Antoni MH, Petronis VM, Weiss S, Derhagopian RP. Optimistic personality and psychosocial well-being during treatment predict psychosocial well-being among long-term survivors of breast cancer. Health Psychol. 2005;24(5):508–16.PubMedGoogle Scholar
  104. 104.
    Tedeschi, RG, Park CL, Lawrence LW, eds. Posttraumatic growth: Positive changes in the aftermath of crisis. Mahwah, NJ: Erlbaum; 1998, JA Schaefer and RH Moos. The context for posttraumatic growth: Life crises, individual and social resources and coping.Google Scholar
  105. 105.
    Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P. Sources of support and the physical and mental well-being of young women with breast cancer. Soc Sci Med. 2001;53(11):1513–24.PubMedGoogle Scholar
  106. 106.
    Schroevers MJ, Ranchor AV, Sanderman R. The role of social support and self-esteem in the presence and course of depressive symptoms: a comparison of cancer patients and individuals from the general population. Soc Sci Med. 2003;57(2):375–85.PubMedGoogle Scholar
  107. 107.
    Norum J, Risberg T, Solberg E. Faith among patients with advanced cancer. A pilot study on patients offered “no more than” palliation. Support Care Cancer. 2000;8(2):110–4.PubMedGoogle Scholar
  108. 108.
    Halstead MT, Fernsler JI. Coping strategies of long-term cancer survivors. Cancer Nurs. 1994;17(2):94–100.PubMedGoogle Scholar
  109. 109.
    Bellizzi KM, Miller MF, Arora NK, Rowland JH. Positive and negative life changes experienced by survivors of non-Hodgkin’s lymphoma. Ann Behav Med. 2007;34(2):188–99.PubMedGoogle Scholar
  110. 110.
    Bellizzi KM, Blank TO. Cancer-related identity and positive affect in survivors of prostate cancer. J Cancer Surviv. 2007;1(1):44–8.PubMedGoogle Scholar
  111. 111.
    Gall TL, Cornblat MW. Breast cancer survivors give voice: a qualitative analysis of spiritual factors in long-term adjustment. Psychooncology. 2002;11(6):524–35.PubMedGoogle Scholar
  112. 112.
    Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008;26(21):3536–42.PubMedGoogle Scholar
  113. 113.
    Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg. 2007;59(4):464–72.PubMedGoogle Scholar
  114. 114.
    Vignes S, Arrault M, Dupuy A. Factors associated with increased breast cancer-related lymphedema volume. Acta Oncol. 2007;46(8):1138–42.PubMedGoogle Scholar
  115. 115.
    Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005;3(4):208–17.PubMedGoogle Scholar
  116. 116.
    Golshan M, Martin WJ, Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg. 2003;69(3):209–11.PubMedGoogle Scholar
  117. 117.
    Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000;55(1):58–61.PubMedGoogle Scholar
  118. 118.
    Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1, 870 consecutive radical retropubic prostatectomies. J Urol. 1999;162(2):433–8.PubMedGoogle Scholar
  119. 119.
    Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991;145(5):998–1002.PubMedGoogle Scholar
  120. 120.
    Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer. 1981;47(12):2810–6.PubMedGoogle Scholar
  121. 121.
    Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302.PubMedGoogle Scholar
  122. 122.
    Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2.PubMedGoogle Scholar
  123. 123.
    Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3–15.PubMedGoogle Scholar
  124. 124.
    Grober SE. Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Pract. 2002;10(4):216–8.PubMedGoogle Scholar
  125. 125.
    de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol. 2004;15(6):896–905.PubMedGoogle Scholar
  126. 126.
    Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104(10):2222–33.PubMedGoogle Scholar
  127. 127.
    Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005;9(2):189–93.PubMedGoogle Scholar
  128. 128.
    Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5(3):273–80.PubMedGoogle Scholar
  129. 129.
    Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20(6):719–25.PubMedGoogle Scholar
  130. 130.
    Tangpong J, Cole MP, Sultana R, Estus S, Vore M, St Clair W, et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem. 2007;100(1):191–201.PubMedGoogle Scholar
  131. 131.
    Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer – preliminary results of an observational longitudinal study. Breast. 2005;14(2):142–50.PubMedGoogle Scholar
  132. 132.
    Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828–34.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835–41.PubMedGoogle Scholar
  134. 134.
    Stovall M, Smith SA, Langholz BM, Boice JD, Shore RE, Andersson M, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys. 2008;72(4):1021–30.PubMedPubMedCentralGoogle Scholar
  135. 135.
    de Berrington Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102(1):220–6.Google Scholar
  136. 136.
    Moreno M, Aristu J, Ramos LI, Arbea L, Lopez-Picazo JM, Cambeiro M, et al. Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer. Clin Transl Oncol. 2007;9(9):596–602.PubMedGoogle Scholar
  137. 137.
    Kocak Z, Evans ES, Zhou SM, Miller KL, Folz RJ, Shafman TD, et al. Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):635–8.PubMedGoogle Scholar
  138. 138.
    Krasin MJ, Constine LS, Friedman DL, Marks LB. Radiation-related treatment effects across the age spectrum: differences and similarities or what the old and young can learn from each other. Semin Radiat Oncol. 2010;20(1):21–9.PubMedPubMedCentralGoogle Scholar
  139. 139.
    Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice Jr JD. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158(2):220–35.PubMedGoogle Scholar
  140. 140.
    Coletti D, Ord RA. Treatment rationale for pathological fractures of the mandible: a series of 44 fractures. Int J Oral Maxillofac Surg. 2008;37(3):215–22.PubMedGoogle Scholar
  141. 141.
    Engleman MA, Woloschak G, Small Jr W. Radiation-induced skeletal injury. Cancer Treat Res. 2006;128:155–69.PubMedGoogle Scholar
  142. 142.
    Paulino AC. Late effects of radiotherapy for pediatric extremity sarcomas. Int J Radiat Oncol Biol Phys. 2004;60(1):265–74.PubMedGoogle Scholar
  143. 143.
    Indelicato DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Marcus Jr RB. Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys. 2008;72(3):871–7.PubMedGoogle Scholar
  144. 144.
    Silber JH, Littman PS, Meadows AT. Stature loss following skeletal irradiation for childhood cancer. J Clin Oncol. 1990;8(2):304–12.PubMedGoogle Scholar
  145. 145.
    Eifel PJ, Donaldson SS, Thomas PR. Response of growing bone to irradiation: a proposed late effects scoring system. Int J Radiat Oncol Biol Phys. 1995;31(5):1301–7.PubMedGoogle Scholar
  146. 146.
    Merchant TE, Nguyen L, Nguyen D, Wu S, Hudson MM, Kaste SC. Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(2):556–61.PubMedGoogle Scholar
  147. 147.
    Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290(4):465–75.PubMedGoogle Scholar
  148. 148.
    Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002;94(3):182–92.PubMedGoogle Scholar
  149. 149.
    Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86.PubMedGoogle Scholar
  150. 150.
    Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol. 1998;46(1):51–62.PubMedGoogle Scholar
  151. 151.
    Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9.PubMedGoogle Scholar
  152. 152.
    Machann, W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 2011;79(4):1117–23.Google Scholar
  153. 153.
    Vallis KA, Pintilie M, Chong N, Holowaty E, Douglas PS, Kirkbride P, et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol. 2002;20(4):1036–42.PubMedGoogle Scholar
  154. 154.
    Rutqvist LE, Liedberg A, Hammar N, Dalberg K. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys. 1998;40(2):359–63.PubMedGoogle Scholar
  155. 155.
    Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol). 2005;17(3):153–9.Google Scholar
  156. 156.
    Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer. 1992;69(5):1241–7.PubMedGoogle Scholar
  157. 157.
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270(16):1949–55.PubMedGoogle Scholar
  158. 158.
    Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The fatigue coalition. Semin Hematol. 1997;34(3 Suppl 2):4–12.PubMedGoogle Scholar
  159. 159.
    Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat. 1996;38(2):183–99.PubMedGoogle Scholar
  160. 160.
    Ahn SH, Park BW, Noh DY, Nam SJ, Lee ES, Lee MK, et al. Health-related quality of life in disease-free survivors of breast cancer with the general population. Ann Oncol. 2007;18(1):173–82.PubMedGoogle Scholar
  161. 161.
    Kornblith AB, Herndon 2nd JE, Weiss RB, Zhang C, Zuckerman EL, Rosenberg S, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98(4):679–89.PubMedGoogle Scholar
  162. 162.
    Dorval M, Maunsell E, Deschenes L, Brisson J, Masse B. Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol. 1998;16(2):487–94.PubMedGoogle Scholar
  163. 163.
    Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002;94(1):39–49.PubMedGoogle Scholar
  164. 164.
    Blank TO, Bellizzi KM. After prostate cancer: predictors of well-being among long-term prostate cancer survivors. Cancer. 2006;106(10):2128–35.PubMedGoogle Scholar
  165. 165.
    Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12):2772–80.PubMedGoogle Scholar
  166. 166.
    Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97(5):1228–34.PubMedGoogle Scholar
  167. 167.
    Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294–303.PubMedGoogle Scholar
  168. 168.
    Rauch P, Miny J, Conroy T, Neyton L, Guillemin F. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol. 2004;22(2):354–60.PubMedGoogle Scholar
  169. 169.
    Sapp AL, Trentham-Dietz A, Newcomb PA, Hampton JM, Moinpour CM, Remington PL. Social networks and quality of life among female long-term colorectal cancer survivors. Cancer. 2003;98(8):1749–58.PubMedGoogle Scholar
  170. 170.
    Trentham-Dietz A, Remington PL, Moinpour CM, Hampton JM, Sapp AL, Newcomb PA. Health-related quality of life in female long-term colorectal cancer survivors. Oncologist. 2003;8(4):342–9.PubMedGoogle Scholar
  171. 171.
    Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, et al. Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10(12):1160–70.PubMedGoogle Scholar
  172. 172.
    Minton O, Stone P. How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast Cancer Res Treat. 2008;112(1):5–13.PubMedGoogle Scholar
  173. 173.
    Meeske K, Smith AW, Alfano CM, McGregor BA, McTiernan A, Baumgartner KB, et al. Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. Qual Life Res. 2007;16(6):947–60.PubMedGoogle Scholar
  174. 174.
    Kim SH, Son BH, Hwang SY, Han W, Yang JH, Lee S, et al. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage. 2008;35(6):644–55.PubMedGoogle Scholar
  175. 175.
    Haghighat S, Akbari ME, Holakouei K, Rahimi A, Montazeri A. Factors predicting fatigue in breast cancer patients. Support Care Cancer. 2003;11(8):533–8.PubMedGoogle Scholar
  176. 176.
    Robb C, Haley WE, Balducci L, Extermann M, Perkins EA, Small BJ, et al. Impact of breast cancer survivorship on quality of life in older women. Crit Rev Oncol Hematol. 2007;62(1):84–91.PubMedGoogle Scholar
  177. 177.
    Mast ME. Correlates of fatigue in survivors of breast cancer. Cancer Nurs. 1998;21(2):136–42.PubMedGoogle Scholar
  178. 178.
    Woo B, Dibble SL, Piper BF, Keating SB, Weiss MC. Differences in fatigue by treatment methods in women with breast cancer. Oncol Nurs Forum. 1998;25(5):915–20.PubMedGoogle Scholar
  179. 179.
    Katz J, Poleshuck EL, Andrus CH, Hogan LA, Jung BF, Kulick DI, et al. Risk factors for acute pain and its persistence following breast cancer surgery. Pain. 2005;119(1–3):16–25.PubMedGoogle Scholar
  180. 180.
    Poleshuck EL, Katz J, Andrus CH, Hogan LA, Jung BF, Kulick DI, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain. 2006;7(9):626–34.PubMedGoogle Scholar
  181. 181.
    Sclafani LM, Baron RH. Sentinel lymph node biopsy and axillary dissection: added morbidity of the arm, shoulder and chest wall after mastectomy and reconstruction. Cancer J. 2008;14(4):216–22.PubMedGoogle Scholar
  182. 182.
    Steegers MA, Wolters B, Evers AW, Strobbe L, Wilder-Smith OH. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. J Pain. 2008;9(9):813–22.PubMedGoogle Scholar
  183. 183.
    Carpenter JS, Andrykowski MA, Sloan P, Cunningham L, Cordova MJ, Studts JL, et al. Postmastectomy/postlumpectomy pain in breast cancer survivors. J Clin Epidemiol. 1998;51(12):1285–92.PubMedGoogle Scholar
  184. 184.
    Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005;92(2):225–30.PubMedPubMedCentralGoogle Scholar
  185. 185.
    Smith WC, Bourne D, Squair J, Phillips DO, Chambers WA. A retrospective cohort study of post mastectomy pain syndrome. Pain. 1999;83(1):91–5.PubMedGoogle Scholar
  186. 186.
    Hayes SC, Janda M, Cornish B, Newman B. Lymphedema following breast cancer. J Clin Oncol. 2009;27(17):2890.PubMedGoogle Scholar
  187. 187.
    Hayes SC, Reul-Hirche H, Turner J. Exercise and secondary lymphedema: safety, potential benefits, and research issues. Med Sci Sports Exerc. 2009;41(3):483–9.PubMedGoogle Scholar
  188. 188.
    Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR. Lymphedema and quality of life in breast cancer survivors: the Iowa Women’s Health Study. J Clin Oncol. 2008;26(35):5689–96.PubMedPubMedCentralGoogle Scholar
  189. 189.
    Smoot B, Wong J, Cooper B, Wanek L, Topp K, Byl N, et al. Upper extremity impairments in women with or without lymphedema following breast cancer treatment. J Cancer Surviv. 2010;4(2):167–78.PubMedPubMedCentralGoogle Scholar
  190. 190.
    Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27(3):390–7.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D. Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat. 2003;79(1):47–57.PubMedGoogle Scholar
  192. 192.
    Armer JM, Stewart BR, Shook RP. 30-month post-breast cancer treatment lymphoedema. J Lymphoedema. 2009;4(1):14–8.PubMedPubMedCentralGoogle Scholar
  193. 193.
    Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol. 2009;16(7):1959–72.PubMedGoogle Scholar
  194. 194.
    Leidenius M, Leppanen E, Krogerus L, von Smitten K. Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer. Am J Surg. 2003;185(2):127–30.PubMedGoogle Scholar
  195. 195.
    Johansson K, Branje E. Arm lymphoedema in a cohort of breast cancer survivors 10 years after diagnosis. Acta Oncol. 2010;49(2):166–73.PubMedGoogle Scholar
  196. 196.
    Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361(7):664–73.PubMedGoogle Scholar
  197. 197.
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–70.PubMedGoogle Scholar
  198. 198.
    Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am J Med. 2005;118(Suppl 12B):136–41.PubMedGoogle Scholar
  199. 199.
    Andrykowski MA, Curran SL, Carpenter JS, Studts JL, Cunningham L, McGrath PC, et al. Rheumatoid symptoms following breast cancer treatment: a controlled comparison. J Pain Symptom Manage. 1999;18(2):85–94.PubMedGoogle Scholar
  200. 200.
    Yurek D, Farrar W, Andersen BL. Breast cancer surgery: comparing surgical groups and determining individual differences in postoperative sexuality and body change stress. J Consult Clin Psychol. 2000;68(4):697–709.PubMedPubMedCentralGoogle Scholar
  201. 201.
    Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004;96(5):376–87.PubMedGoogle Scholar
  202. 202.
    Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006;15(7):579–94.PubMedGoogle Scholar
  203. 203.
    Arora NK, Gustafson DH, Hawkins RP, McTavish F, Cella DF, Pingree S, et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. Cancer. 2001;92(5):1288–98.PubMedGoogle Scholar
  204. 204.
    Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology. 2004;13(5):295–308.PubMedGoogle Scholar
  205. 205.
    Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051–7.PubMedGoogle Scholar
  206. 206.
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215–23.PubMedGoogle Scholar
  207. 207.
    National Osteoporosis Foundation: Fast Facts. Available at Last accessed on March 7, 2011.
  208. 208.
    Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28(6):967–75.PubMedGoogle Scholar
  209. 209.
    Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, et al. Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775–8.PubMedGoogle Scholar
  210. 210.
    Fan HG, Houede-Tchen N, Yi QL, Chemerynsky I, Downie FP, Sabate K, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005;23(31):8025–32.PubMedGoogle Scholar
  211. 211.
    Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Investig. 2007;25(6):373–7.Google Scholar
  212. 212.
    Kornblith AB, Ligibel J. Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol. 2003;30(6):799–813.PubMedGoogle Scholar
  213. 213.
    Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer. 2005;41(17):2613–9.PubMedGoogle Scholar
  214. 214.
    Maunsell E, Brisson J, Deschenes L. Psychological distress after initial treatment of breast cancer. Assessment of potential risk factors. Cancer. 1992;70(1):120–5.PubMedGoogle Scholar
  215. 215.
    Ganz PA, Lee JJ, Sim MS, Polinsky ML, Schag CA. Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. J Clin Epidemiol. 1992;45(5):473–85.PubMedGoogle Scholar
  216. 216.
    Schag CA, Ganz PA, Polinsky ML, Fred C, Hirji K, Petersen L. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol. 1993;11(4):783–93.PubMedGoogle Scholar
  217. 217.
    Ganz PA, Hirji K, Sim MS, Schag CA, Fred C, Polinsky ML. Predicting psychosocial risk in patients with breast cancer. Med Care. 1993;31(5):419–31.PubMedGoogle Scholar
  218. 218.
    Hartl K, Janni W, Kastner R, Sommer H, Strobl B, Rack B, et al. Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients. Ann Oncol. 2003;14(7):1064–71.PubMedGoogle Scholar
  219. 219.
    King CR, Haberman M, Berry DL, Bush N, Butler L, Dow KH, et al. Quality of life and the cancer experience: the state-of-the-knowledge. Oncol Nurs Forum. 1997;24(1):27–41.PubMedGoogle Scholar
  220. 220.
    Ferrell BR, Grant M, Funk B, Otis-Green S, Garcia N. Quality of life in breast cancer. Part I: Physical and social well-being. Cancer Nurs. 1997;20(6):398–408.PubMedGoogle Scholar
  221. 221.
    Somerset W, Stout SC, Miller AH, Musselman D. Breast cancer and depression. Oncology (Williston Park). 2004;18(8):1021–34.Google Scholar
  222. 222.
    Penson DF, Litwin MS. The physical burden of prostate cancer. Urol Clin North Am. 2003;30(2):305–13.PubMedGoogle Scholar
  223. 223.
    Penson DF, Litwin MS. Quality of life after treatment for prostate cancer. Curr Urol Rep. 2003;4(3):185–95.PubMedGoogle Scholar
  224. 224.
    Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.PubMedGoogle Scholar
  225. 225.
    Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol. 2003;169(5):1653–61.PubMedGoogle Scholar
  226. 226.
    Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(4):1063–8.PubMedGoogle Scholar
  227. 227.
    Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 2000;55(5):736–42.PubMedGoogle Scholar
  228. 228.
    Stone P, Hardy J, Huddart R, A’Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36(9):1134–41.PubMedGoogle Scholar
  229. 229.
    Herr HW, O’Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000;163(6):1743–6.PubMedGoogle Scholar
  230. 230.
    Monga U, Kerrigan AJ, Thornby J, Monga TN, Zimmermann KP. Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. J Rehabil Res Dev. 2005;42(3):391–9.PubMedGoogle Scholar
  231. 231.
    Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fossa SD. Fatigue in hormone-naive prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer Prostatic Dis. 2010;13(2):144–50.PubMedGoogle Scholar
  232. 232.
    Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.PubMedGoogle Scholar
  233. 233.
    Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388–99.PubMedGoogle Scholar
  234. 234.
    Schwandt A, Garcia JA. Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol. 2009;19(3):322–6.PubMedGoogle Scholar
  235. 235.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163(1):181–6.PubMedGoogle Scholar
  236. 236.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.PubMedGoogle Scholar
  237. 237.
    Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79(6):933–41.PubMedGoogle Scholar
  238. 238.
    Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104(8):1633–7.PubMedGoogle Scholar
  239. 239.
    Smith MR, O’Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008;101(11):1335–6.PubMedPubMedCentralGoogle Scholar
  240. 240.
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.PubMedGoogle Scholar
  241. 241.
    Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70(6):1104–8.PubMedGoogle Scholar
  242. 242.
    Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.PubMedGoogle Scholar
  243. 243.
    Manne SL. Prostate cancer support and advocacy groups: their role for patients and family members. Semin Urol Oncol. 2002;20(1):45–54.PubMedGoogle Scholar
  244. 244.
    Mehta SS, Lubeck DP, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol. 2003;170(5):1931–3.PubMedGoogle Scholar
  245. 245.
    Billington A. Prostate cancer and its effect on sexuality. Community Nurse. 1998;4(10):33–4.PubMedGoogle Scholar
  246. 246.
    Moore KN, Estey A. The early post-operative concerns of men after radical prostatectomy. J Adv Nurs. 1999;29(5):1121–9.PubMedGoogle Scholar
  247. 247.
    Braslis KG, Santa-Cruz C, Brickman AL, Soloway MS. Quality of life 12 months after radical prostatectomy. Br J Urol. 1995;75(1):48–53.PubMedGoogle Scholar
  248. 248.
    Jonler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology. 1996;48(3):433–40.PubMedGoogle Scholar
  249. 249.
    Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol. 2003;22(5):443–52.PubMedPubMedCentralGoogle Scholar
  250. 250.
    Butler L, Downe-Wamboldt B, Marsh S, Bell D, Jarvi K. Behind the scenes: partners’ perceptions of quality of life post radical prostatectomy. Urol Nurs. 2000;20(4):254–8.PubMedGoogle Scholar
  251. 251.
    Heyman EN, Rosner TT. Prostate cancer: an intimate view from patients and wives. Urol Nurs. 1996;16(2):37–44.PubMedGoogle Scholar
  252. 252.
    Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Holzel D. Quality of life in rectal cancer patients: a four-year prospective study. Ann Surg. 2003;238(2):203–13.PubMedPubMedCentralGoogle Scholar
  253. 253.
    Fucini C, Gattai R, Urena C, Bandettini L, Elbetti C. Quality of life among five-year survivors after treatment for very low rectal cancer with or without a permanent abdominal stoma. Ann Surg Oncol. 2008;15(4):1099–106.PubMedGoogle Scholar
  254. 254.
    Gosselink MP, Busschbach JJ, Dijkhuis CM, Stassen LP, Hop WC, Schouten WR. Quality of life after total mesorectal excision for rectal cancer. Colorectal Dis. 2006;8(1):15–22.PubMedGoogle Scholar
  255. 255.
    Borwell B. The psychosexual needs of stoma patients. Prof Nurse. 1997;12(4):250–5.PubMedGoogle Scholar
  256. 256.
    Hojo K, Vernava 3rd AM, Sugihara K, Katumata K. Preservation of urine voiding and sexual function after rectal cancer surgery. Dis Colon Rectum. 1991;34(7):532–9.PubMedGoogle Scholar
  257. 257.
    Hurny C, Holland J. Psychosocial sequelae of ostomies in cancer patients. CA Cancer J Clin. 1985;35(3):170–83.PubMedGoogle Scholar
  258. 258.
    Thomas C, Madden F, Jehu D. Psychological effects of stomas – I. Psychosocial morbidity one year after surgery. J Psychosom Res. 1987;31(3):311–6.PubMedGoogle Scholar
  259. 259.
    Krouse R, Grant M, Ferrell B, Dean G, Nelson R, Chu D. Quality of life outcomes in 599 cancer and non-cancer patients with colostomies. J Surg Res. 2007;138(1):79–87.PubMedGoogle Scholar
  260. 260.
    Krouse RS, Grant M, Wendel CS, Mohler MJ, Rawl SM, Baldwin CM, et al. A mixed-methods evaluation of health-related quality of life for male veterans with and without intestinal stomas. Dis Colon Rectum. 2007;50(12):2054–66.PubMedGoogle Scholar
  261. 261.
    Baldwin CM, Grant M, Wendel C, Rawl S, Schmidt CM, Ko C, et al. Influence of intestinal stoma on spiritual quality of life of U.S. veterans. J Holist Nurs. 2008;26(3):185–94.PubMedGoogle Scholar
  262. 262.
    Sprangers MA, Taal BG, Aaronson NK, te Velde A. Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum. 1995;38(4):361–9.PubMedGoogle Scholar
  263. 263.
    Pikarsky AJ, Belin B, Efron J, Weiss EG, Nogueras JJ, Wexner SD. Complications following formalin installation in the treatment of radiation induced proctitis. Int J Colorectal Dis. 2000;15(2):96–9.PubMedGoogle Scholar
  264. 264.
    Buchi K. Radiation proctitis: therapy and prognosis. JAMA. 1991;265(9):1180.PubMedGoogle Scholar
  265. 265.
    Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76(4):1012–7.PubMedGoogle Scholar
  266. 266.
    Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005;294(20):2587–93.PubMedGoogle Scholar
  267. 267.
    Baxter NN, Hartman LK, Tepper JE, Ricciardi R, Durham SB, Virnig BA. Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgery. Ann Surg. 2007;245(4):553–9.PubMedPubMedCentralGoogle Scholar
  268. 268.
    White CA, Hunt JC. Psychological factors in postoperative adjustment to stoma surgery. Ann R Coll Surg Engl. 1997;79(1):3–7.PubMedPubMedCentralGoogle Scholar
  269. 269.
    Krouse RS, Herrinton LJ, Grant M, Wendel CS, Green SB, Mohler MJ, et al. Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. J Clin Oncol. 2009;27(28):4664–70.PubMedPubMedCentralGoogle Scholar
  270. 270.
    American Cancer Society. Hodgkin Disease. Available at Last accessed on March 7, 2011.
  271. 271.
    Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003;104(4):488–95.PubMedGoogle Scholar
  272. 272.
    Arden-Close E, Pacey A, Eiser C. Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma. 2010;51(4):628–40.PubMedGoogle Scholar
  273. 273.
    King V, Constine LS, Clark D, Schwartz RG, Muhs AG, Henzler M, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1996;36(4):881–9.PubMedGoogle Scholar
  274. 274.
    Lund MB, Ihlen H, Voss BM, Abrahamsen AF, Nome O, Kongerud J, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin’s disease: an echocardiographic study. Heart. 1996;75(6):591–5.PubMedPubMedCentralGoogle Scholar
  275. 275.
    Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, et al. Long-term survival in Hodgkin’s disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995;1(1):33–42.PubMedGoogle Scholar
  276. 276.
    Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20(16):3484–94.PubMedGoogle Scholar
  277. 277.
    Meattini I, Livi L, Saieva C, Marrazzo L, Rampini A, Iermano C, et al. Breast cancer following Hodgkin’s disease: the experience of the university of Florence. Breast J. 2010;16(3):290–6.PubMedGoogle Scholar
  278. 278.
    Aleman BM, van Leeuwen FE. Are we improving the long-term burden of Hodgkin’s lymphoma patients with modern treatment? Hematol Oncol Clin North Am. 2007;21(5):961–75.PubMedGoogle Scholar
  279. 279.
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431–9.PubMedGoogle Scholar
  280. 280.
    Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: university of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48(1):169–79.PubMedGoogle Scholar
  281. 281.
    Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, et al. Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002;13(11):1786–91.PubMedGoogle Scholar
  282. 282.
    Tinger A, Wasserman TH, Klein EE, Miller EA, Roberts T, Piephoff JV, et al. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys. 1997;37(4):865–70.PubMedGoogle Scholar
  283. 283.
    Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498–509.PubMedGoogle Scholar
  284. 284.
    Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med. 1988;318(2):76–81.PubMedGoogle Scholar
  285. 285.
    Cellai E, Magrini SM, Masala G, Alterini R, Costantini AS, Rigacci L, et al. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin’s disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys. 2001;49(5):1327–37.PubMedGoogle Scholar
  286. 286.
    Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005;106(10):3358–65.PubMedPubMedCentralGoogle Scholar
  287. 287.
    van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van’t Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst. 2003;95(13):971–80.PubMedGoogle Scholar
  288. 288.
    M’Kacher R, Girinsky T, Koscielny S, Dossou J, Violot D, Béron-Gaillard N, et al. Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin’s lymphoma patients. Int J Radiat Oncol Biol Phys. 2003;57(2):321–6.PubMedGoogle Scholar
  289. 289.
    Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18(12):2435–43.PubMedGoogle Scholar
  290. 290.
    Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101–8.PubMedGoogle Scholar
  291. 291.
    Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97(19):1428–37.PubMedGoogle Scholar
  292. 292.
    Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med. 1996;334(12):745–51.PubMedGoogle Scholar
  293. 293.
    Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005;34:25–7.PubMedGoogle Scholar
  294. 294.
    Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85(9):3227–32.PubMedGoogle Scholar
  295. 295.
    Khoo VS, Liew KH, Crennan EC, D’Costa IM, Quong G. Thyroid dysfunction after mantle irradiation of Hodgkin’s disease patients. Australas Radiol. 1998;42(1):52–7.PubMedGoogle Scholar
  296. 296.
    Zebrack BJ, Zeltzer LK, Whitton J, Mertens AC, Odom L, Berkow R, et al. Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin’s disease, and non-Hodgkin’s lymphoma: a report from the Childhood Cancer Survivor Study. Pediatrics. 2002;110(1 Pt 1):42–52.PubMedGoogle Scholar
  297. 297.
    Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC. Post-traumatic stress outcomes in non-Hodgkin’s lymphoma survivors. J Clin Oncol. 2008;26(6):934–41.PubMedPubMedCentralGoogle Scholar
  298. 298.
    United States Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder: How Common is PTSD? Available at Last accessed on March 7, 2011.
  299. 299.
    Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academy Press; 2005.Google Scholar
  300. 300.
    Lyne ME, Coyne PJ, Watson AC. Pain management issues for cancer survivors. Cancer Pract. 2002;10 Suppl 1:S27–32.PubMedGoogle Scholar
  301. 301.
    National Cancer Institute. Cancer care outcomes research and surveillance consortium. (2010). Last assessed 4 May 2010.

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Health Care PolicyHarvard Medical SchoolBostonUSA

Personalised recommendations